On March 18, 2025, Richard Byrd, Executive Vice President & President of Interventional at Becton Dickinson & Co (BDX, Financial), sold 459 shares of the company. Following this transaction, the insider now owns 6,952 shares of the company. The details of this transaction can be found in the SEC Filing.
Becton Dickinson & Co (BDX) is a global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Over the past year, Richard Byrd has sold a total of 2,399 shares and has not purchased any shares. The insider transaction history for Becton Dickinson & Co shows that there have been 1 insider buy and 15 insider sells over the same timeframe.
On the day of the recent sale, shares of Becton Dickinson & Co were trading at $230 each, giving the stock a market cap of $65.846 billion. The company's price-earnings ratio is 38.09, which is higher than the industry median of 26.83 but lower than the company’s historical median price-earnings ratio.
With a price of $230 and a GuruFocus Value of $263.62, Becton Dickinson & Co has a price-to-GF-Value ratio of 0.87. This indicates that the stock is modestly undervalued based on its GF Value. The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on historical multiples, a GuruFocus adjustment factor, and future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
